e.g. mhealth
Search Results (1 to 10 of 54 Results)
Download search results: CSV END BibTex RIS
Skip search results from other journals and go to results- 15 JMIR Research Protocols
- 10 Journal of Medical Internet Research
- 9 JMIR mHealth and uHealth
- 8 JMIR Cancer
- 5 JMIR Formative Research
- 2 JMIR Medical Informatics
- 1 JMIR Dermatology
- 1 JMIR Human Factors
- 1 JMIR Nursing
- 1 JMIR Public Health and Surveillance
- 1 JMIR Serious Games
- 0 Medicine 2.0
- 0 Interactive Journal of Medical Research
- 0 iProceedings
- 0 JMIR Mental Health
- 0 JMIR Rehabilitation and Assistive Technologies
- 0 JMIR Preprints
- 0 JMIR Bioinformatics and Biotechnology
- 0 JMIR Medical Education
- 0 JMIR Challenges
- 0 JMIR Diabetes
- 0 JMIR Biomedical Engineering
- 0 JMIR Data
- 0 JMIR Cardio
- 0 Journal of Participatory Medicine
- 0 JMIR Pediatrics and Parenting
- 0 JMIR Aging
- 0 JMIR Perioperative Medicine
- 0 JMIRx Med
- 0 JMIRx Bio
- 0 JMIR Infodemiology
- 0 Transfer Hub (manuscript eXchange)
- 0 JMIR AI
- 0 JMIR Neurotechnology
- 0 Asian/Pacific Island Nursing Journal
- 0 Online Journal of Public Health Informatics
- 0 JMIR XR and Spatial Computing (JMXR)
Before a new chemotherapy cycle, a patient’s laboratory values and symptoms were evaluated, for example, for indications of treatable chemotherapy side effects, excess chemotherapy toxicity, and cancer progression. To streamline this work process, increase the comprehensiveness and repeatability of the precycle evaluation, and automate duties, we developed a decision support tool.
JMIR Form Res 2025;9:e62749
Download Citation: END BibTex RIS
End-of-treatment chemotherapy-induced peripheral neuropathy detection performance by Neuro Detect, CIPN20, and Combined Models.
a CIPN-f: chemotherapy-induced peripheral neuropathy in the feet.
b CIPN-h: chemotherapy-induced peripheral neuropathy in the hands.
c CIPN20: 20-item scale.
d NIR: no information rate.
e P value testing accuracy of each Model versus the no information rate, which is the accuracy obtained by always predicting the majority class.
f Significance level P
Predicted chemotherapy-induced peripheral
J Med Internet Res 2025;27:e65615
Download Citation: END BibTex RIS
Chemotherapy can cause significant symptoms that impact the quality of life [1]. Although electronic patient-reported outcome (e PRO) systems for collecting symptom ratings from patients have become increasingly common in cancer care, most of these are designed for clinicians, and fewer than half share data visualizations with the patients [2,3].
JMIR Cancer 2025;11:e62711
Download Citation: END BibTex RIS
Men and women aged 18 years or older who were undergoing chemotherapy for any solid tumor at a large academic cancer center, who owned a smartphone, who could read and write in English, and who had at least 2 chemotherapy cycles remaining were eligible to participate. In addition, 7 participants were recruited from a community research registry, and these participants were asked to self-report on if they met the above eligibility criteria.
JMIR Cancer 2024;10:e57347
Download Citation: END BibTex RIS
For patients in the usual care group, upon admission, patients were provided with admission counseling, given an explanation about the complications associated with chemotherapy, and given a chemotherapy care booklet and a leaflet on diet and nutrition. Before discharge, the patients were given the nutritional guidebook again. Responsible nurses made 1 telephone follow-up visit between chemotherapy sessions.
JMIR Mhealth Uhealth 2024;12:e56475
Download Citation: END BibTex RIS
Impact of Patient Personality on Adherence to Oral Anticancer Medications: An Opportunity?
While oral anticancer medications have many advantages over parenteral chemotherapy, including eliminating the need for venous access devices, many patients struggle with adhering to their prescribed regimens. Whereas medication adherence rates among patients with chronic diseases on oral treatment are estimated at approximately 50%, adherence rates for oral anticancer medications are substantially lower, with studies reporting adherence rates as low as 30% to 46% in patients with cancer [1-3].
JMIR Cancer 2024;10:e57199
Download Citation: END BibTex RIS
In oncology, DAs have been used since at least the advent of the “Decision Board” in 1992 for adjuvant chemotherapy in node-negative breast cancer [9,10], and although considerable research exists on their use and efficacy in oncology as a whole, and products do exist commercially [11], there is little in the current literature examining the development and efficacy of DAs targeting the unique challenges of oral chemotherapy.
JMIR Cancer 2024;10:e56935
Download Citation: END BibTex RIS
At least one-third of women undergoing adjuvant chemotherapy treatment for breast cancer are unable to complete the prescribed dose of treatment due to adverse effects, thus compromising the prognosis of the disease [5].
Physical exercise in patients with cancer during chemotherapy has been tested in randomized trials [5-11] and appears to improve physical function, fatigue, symptom burden, and the quality of life of patients, in addition to allowing the nonreduction of chemotherapy doses.
JMIR Res Protoc 2024;13:e60828
Download Citation: END BibTex RIS
One of the first studies to explore the use of predictive risk modeling (PRM) in supportive care developed and tested a symptom risk modeling tool for patients with breast cancer undergoing adjuvant chemotherapy and demonstrated a high level of accuracy in predicting 4 out of 6 symptoms [28].
J Med Internet Res 2024;26:e49309
Download Citation: END BibTex RIS
Patients with advanced cancer who receive chemotherapy often experience significant symptoms, declines in functional status, and hospitalization [1-3]. Patient-reported outcomes (PROs) measure symptom burden and well-being. In clinical trials, routine collection of PROs for patients with cancer undergoing treatment is associated with decreased acute care use and improved overall survival [4,5].
J Med Internet Res 2024;26:e51059
Download Citation: END BibTex RIS